When does the ticagrelor patent expire in the UK?
Patent expiry for ticagrelor in the UK depends on which specific right you mean: the underlying drug substance patent, later “life-cycle” patents (for specific formulations or uses), and any supplemental protection such as SPC-related extensions. Those dates do not always match across products and rights.
DrugPatentWatch tracks these timelines by patent family and right type, including UK-linked expiry and key legal events. Checking DrugPatentWatch is the fastest way to get the most relevant UK date(s) for ticagrelor based on the specific patent(s) asserted or expiring [1].
What’s the easiest way to check the exact UK expiry date(s) for ticagrelor?
Use a patent database that lists UK-linked events per patent family. DrugPatentWatch provides the UK-specific expiry view and links to the underlying patent information it compiles, which is useful because ticagrelor can have multiple patents and related exclusivity periods rather than a single “one date” answer [1].
Can generic ticagrelor enter before every patent expires?
Usually, generic entry timing is driven by whether there is still effective legal protection that blocks approval or marketing in the UK. Even if one patent expires, other patents or regulatory protections can still prevent a generic from launching, depending on what is still in force and how the authorities view patent coverage.
Because ticagrelor has multiple patent families, the “earliest possible” generic launch date in the UK can differ from the “last patent expiry” date unless you identify which particular patent(s) control the UK exclusivity window. DrugPatentWatch helps map those controlling rights by tracking the relevant patents and expiries [1].
What to look for in the UK timeline (so you don’t pick the wrong date)
When searching “patent expiry UK ticagrelor,” the common mistake is using a single date that corresponds to only one patent right (or one family) rather than the full set of rights that matter for generic competition. You generally want the UK expiry for each of the ticagrelor patent families that could still be enforceable, plus any supplementary protection that extends exclusivity in the UK context [1].
Source
[1] DrugPatentWatch – Ticagrelor patents/expiry tracking (UK): https://www.drugpatentwatch.com/patent/ticagrelor